Jacobio Strikes Up to US$1.9 Billion Global KRAS Inhibitor Deal With AstraZeneca

Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) has shared an announcement.

Jacobio Pharmaceuticals has entered into a global licence and collaboration agreement with AstraZeneca for its pan-KRAS inhibitor JAB-23E73, granting AstraZeneca exclusive rights to develop, register, manufacture and commercialize the drug worldwide outside mainland China, while the two companies will jointly develop and co-commercialize the product in the mainland China market under a shared governance and cost framework. Under the deal, Beijing Jacobio will receive an upfront payment of US$100 million and may earn up to US$1.915 billion in additional development, regulatory and commercial milestone payments plus tiered royalties on net sales, a structure that significantly strengthens Jacobio’s funding and positions it to expand its international partnerships and maximize the scientific and commercial value of its oncology technology platforms as JAB-23E73 advances in trials targeting KRAS-mutant solid tumors such as pancreatic, lung and colorectal cancers.

The most recent analyst rating on (HK:1167) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.

More about Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd., through its indirect controlled subsidiary Beijing Jacobio, is a China-based biopharmaceutical company focused on the in-house discovery and development of innovative oncology therapies. Its pipeline includes targeted cancer drugs such as JAB-23E73, a pan-KRAS inhibitor being tested in Phase I clinical trials in China and the United States for patients with advanced solid tumors harboring KRAS gene alterations.

Average Trading Volume: 5,962,751

Technical Sentiment Signal: Buy

Current Market Cap: HK$7.17B

See more data about 1167 stock on TipRanks’ Stock Analysis page.